Radio-223 radiotherapy
What is it?
Radium 223 is an α-emitting radionuclide, characterized by high power and a small radius of activity that allows to destroy only tumor cells located in the immediate vicinity to the target. Radium 223 is the first radiopharmaceutical with specific effect on bone tissue that not only decreases skeletal complications but also increases bone survival.
When is this procedure indicated?
Bone metastatic castrate resistant prostate cancer.
How is it performed?
Ra-223 is administered intravenously by slow injection (usually up to 1 minute) at 4 weeks ± 7 days intervals, using 6 injections. Unless clinically necessary, discharge will be on a same-day basis. The most frequently observed unfavorable reactions (≥10%) in patients treated with Ra-223 were diarrhea, nausea, vomiting, and thrombocytopenia. The most serious side effects are thrombocytopenia and neutropenia. Hypersensitivity reactions including anaphylactic and anaphylactoid allergic reactions are also possible, although rarely observed.
Contraindications
No other known contraindications to the use of Ra-223.
Are you interested in receiving the treatment?